Executive Summary
The suit was decreed for the lifetime of Indian Patent No. 237430, prohibiting the defendants from manufacturing or selling pharmaceutical preparations containing Nilotinib.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court - Orders. Understanding the court's reasoning in Novartis A G vs Supermax Drugs And Pharmaceuticals is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Emd Millipore CorporationvsAssistant Controller Of Patents And Designs
The Delhi High Court heard several part-heard matters. In C.A.(COMM.IPD-PAT) 16/2023, the court noted that the Patent Office had submitted a report concerning issues related to inventive steps, subject matter eligibility, and amendment under the Patents Act, 1970.
Mohammed Azam Trading As M/S Noor AhmedvsParamjeet Singh & Anr.
The Delhi High Court issued a significant interim order in favor of the plaintiff, Mohammed Azam Trading As M/S Noor Ahmed. The court granted an immediate interim injunction, restraining the defendants from using the infringing mark 'NURY/' while the main suit proceeds. Furthermore, the court allowed the plaintiff to file additional documents and exempted them from pre-institution mediation, setting a clear path for the litigation's progression.
M/S RSPL HEALTH PRIVATE LIMITEDvsGovind Rathore
The plaintiff, M/S RSPL Health Private Limited, filed a commercial suit alleging infringement and passing off under the Trademarks Act, 1999, and Copyright Act, 1957. The dispute centered on the unauthorized use of the plaintiff's registered trademarks (GHARI/GHADI) and associated trade dress by the defendants in relation to FMCG goods like soap and detergents. The court decreed the suit in favor of the plaintiff.
Novartis AgvsMedipol Pharmaceuticals India Pvt Ltd
The plaintiff, Novartis Ag, filed a suit alleging infringement of its patent (IN 233161) concerning the drug Eltrombopag Olamine. The court found a clear prima facie case in favor of the plaintiff, noting that the rights to the patent had been confirmed previously.
F.Hoffmann-La Roche LtdvsMylan Laboratories Limited
F.Hoffmann-La Roche Ltd filed a petition seeking the revocation of Patent No. 205706 held by Mylan Laboratories Limited and the Controller of Patents. However, the court noted that the term of Patent No. 205706 had already expired on June 4, 2021.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.